Rivaroxaban With or Without Aspirin in Patients with Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial.

CONCLUSIONS: In patients with chronic CAD or PAD and a history of mild or moderate HF, combination rivaroxaban and aspirin compared with aspirin alone produces similar relative but larger absolute benefits compared with those without HF. CLINICAL TRIAL REGISTRATION: Unique Identifier: NCT01776424 URL: https://clinicaltrials.gov. PMID: 31163978 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31163978?dopt=Abstract

Source: Circulation - June 4, 2019 Category: Cardiology Authors: Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK, Bhatt DL, Avezum A, Fox KAA, Connolly SJ, Shestakovska O, Yusuf S Tags: Circulation Source Type: research